Mechanisms underlying the anti-epileptic efficacy of the ketogenic diet

P A Schwartzkroin1

  • 1Department of Neurological Surgery and Physiology/Biophysics, University of Washington, Seattle 98195-6470, USA. pas@u.washington.edu

Epilepsy Research
|December 10, 1999
PubMed

Insights

The ketogenic diet (KD) is clinically effective for epilepsy, but its mechanisms remain unclear. Further research using animal models is needed to test hypotheses about KD

Area of Science:

  • Neuroscience
  • Metabolic Disorders
  • Epilepsy Research

Background:

  • The clinical effectiveness of the ketogenic diet (KD) for epilepsy is well-established.
  • However, the precise biological mechanisms underlying its antiepileptic effects are not fully understood and require further investigation.

Purpose of the Study:

  • To explore and categorize the leading hypotheses regarding the mechanisms of the ketogenic diet's (KD) antiepileptic efficacy.
  • To highlight the need for rigorous testing of these hypotheses using appropriate animal models.

Main Methods:

  • Review and synthesis of existing hypotheses on KD mechanisms.
  • Identification of key areas for experimental investigation, including energy metabolism, cellular properties, neurotransmission, circulating factors, and the brain extracellular milieu.
  • Emphasis on the necessity of developing and utilizing animal models for hypothesis testing.

Main Results:

  • Several major hypotheses regarding KD's antiepileptic mechanisms have been proposed.
  • These include alterations in brain energy metabolism, neuronal and glial cell properties, neurotransmitter function, circulating neuromodulators, and the brain extracellular environment.

Conclusions:

  • Understanding the mechanistic basis of the ketogenic diet's (KD) efficacy is crucial for optimizing its clinical application in epilepsy management.
  • Elucidating these mechanisms may also pave the way for the development of novel antiepileptic therapies.

Related Concept Videos

Epilepsy and Seizures: Overview01:24

Epilepsy and Seizures: Overview

Epilepsy is a chronic neurological disease marked by recurrent, unpredictable seizures. These seizures are caused by abnormal electrical discharges in the brain, leading to behavior, sensation, or consciousness alterations. They can also cause transient impairment of awareness, interfering with daily activities.
Various factors can trigger epilepsy, including genetic factors, brain damage, metabolic causes, and unknown etiology. Diagnosis of epilepsy involves electroencephalography (EEG), which...
Antiepileptic Drugs: GABAergic Pathway Potentiators01:18

Antiepileptic Drugs: GABAergic Pathway Potentiators

γ-aminobutyric acid or GABA, plays a pivotal role as an inhibitory neurotransmitter in the brain. GABA pathway potentiators, also known as GABAergic drugs, are a class of pharmaceutical agents designed to enhance the functioning of the GABAergic system. These medications primarily treat epilepsy, a neurological disorder characterized by recurrent seizures.
The key GABA pathway potentiators used in epilepsy management are as follows.
Benzodiazepines are a well-known class of drugs used for their...
Antiepileptic Drugs: Glutamate Antagonists01:14

Antiepileptic Drugs: Glutamate Antagonists

Glutamate is a fundamental neurotransmitter in the central nervous system, playing a vital role in neuronal communication and various cognitive processes. Glutamate stands as the principal excitatory neurotransmitter in the brain. Its presence is crucial for the communication between neurons, underpinning essential processes such as synaptic transmission, neuronal excitability, and plasticity. These functions are vital for higher-order cognitive processes, including learning and memory. The...
Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein01:20

Antiepileptic Drugs: Modulators of Neurotransmitter Release Mediated by SV2A Protein

Antiepileptic drugs, such as levetiracetam (Keppra) and brivaracetam (Briviact), have emerged as crucial tools in managing epilepsy. These medications exert their therapeutic effects by targeting the synaptic vesicle protein SV2A, a transmembrane glycoprotein primarily found in the brain.
SV2A is a transmembrane glycoprotein located predominantly in the brain, modulating the release of neurotransmitters for neuronal communication. Both levetiracetam and brivaracetam exhibit a high affinity for...
Antiepileptic Drugs: Potassium Channel Activators01:20

Antiepileptic Drugs: Potassium Channel Activators

Ezocgabine or retigabine, an antiepileptic drug of remarkable efficacy, has revolutionized the management of seizures. It is a potassium channel activator, explicitly targeting the family of Q subtype potassium channels. It enhances the transmembrane potassium currents, regulating neuronal excitability. This action stabilizes the resting membrane potential, a pivotal factor in mitigating the hyperexcitability that characterizes epilepsy.
Ezogabine has gained approval as an adjunctive treatment...
Diabetic Ketoacidosis ll: Pathophysiology01:22

Diabetic Ketoacidosis ll: Pathophysiology

Diabetic ketoacidosis (DKA) is a metabolic emergency characterized by hyperglycemia, ketonemia, and metabolic acidosis. It results from severe insulin deficiency and an excess of counterregulatory hormones, leading to uncontrolled lipolysis, ketogenesis, and widespread electrolyte and fluid disturbances.Pathophysiology The central event in DKA is a profound loss of insulin action. Without insulin, glucose uptake in insulin-dependent tissues is impaired, while hepatic glucose production...